beamsplitters Search Results


tunable quantum beam splitters  (Coherent Corp)
92
Coherent Corp tunable quantum beam splitters
Tunable Quantum Beam Splitters, supplied by Coherent Corp, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/beamsplitters/10__1103_slash_physrevx__1__011003-146-16-21?v=Coherent+Corp
Average 92 stars, based on 1 article reviews
tunable quantum beam splitters - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier
ova igg1  (Chondrex Inc)
94
Chondrex Inc ova igg1
Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA <t>IgG1</t> and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.
Ova Igg1, supplied by Chondrex Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/beamsplitters/pmc13137760-331-3-22?v=Chondrex+Inc
Average 94 stars, based on 1 article reviews
ova igg1 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
triple-pass beamsplitter  (Carl Zeiss)
90
Carl Zeiss triple-pass beamsplitter
Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA <t>IgG1</t> and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.
Triple Pass Beamsplitter, supplied by Carl Zeiss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/beamsplitters/pmc04215772-188-28-34?v=Carl+Zeiss
Average 90 stars, based on 1 article reviews
triple-pass beamsplitter - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
zeiss 50/25/25 beamsplitter  (Carl Zeiss)
90
Carl Zeiss zeiss 50/25/25 beamsplitter
Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA <t>IgG1</t> and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.
Zeiss 50/25/25 Beamsplitter, supplied by Carl Zeiss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/beamsplitters/pmc03970814-83-13-9?v=Carl+Zeiss
Average 90 stars, based on 1 article reviews
zeiss 50/25/25 beamsplitter - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
dichroic beamsplitter ft580  (Carl Zeiss)
90
Carl Zeiss dichroic beamsplitter ft580
Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA <t>IgG1</t> and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.
Dichroic Beamsplitter Ft580, supplied by Carl Zeiss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/beamsplitters/pmc04905513-89-18-21?v=Carl+Zeiss
Average 90 stars, based on 1 article reviews
dichroic beamsplitter ft580 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
beamsplitter  (Carl Zeiss)
90
Carl Zeiss beamsplitter
Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA <t>IgG1</t> and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.
Beamsplitter, supplied by Carl Zeiss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/beamsplitters/pm18769914-93-43-52?v=Carl+Zeiss
Average 90 stars, based on 1 article reviews
beamsplitter - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
lsm 5 exciter 527  (Carl Zeiss)
90
Carl Zeiss lsm 5 exciter 527
Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA <t>IgG1</t> and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.
Lsm 5 Exciter 527, supplied by Carl Zeiss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/beamsplitters/10__1021_slash_acs__bioconjchem__7b00551-281-8-12?v=Carl+Zeiss
Average 90 stars, based on 1 article reviews
lsm 5 exciter 527 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
beamsplitter dualview  (Photometrics Inc)
90
Photometrics Inc beamsplitter dualview
Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA <t>IgG1</t> and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.
Beamsplitter Dualview, supplied by Photometrics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/beamsplitters/pmc03173513-370-16-18?v=Photometrics+Inc
Average 90 stars, based on 1 article reviews
beamsplitter dualview - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
beamsplitter matrix  (Verlag GmbH)
90
Verlag GmbH beamsplitter matrix
Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA <t>IgG1</t> and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.
Beamsplitter Matrix, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/beamsplitters/10__1002_slash_qute__201800011-526-15-5?v=Verlag+GmbH
Average 90 stars, based on 1 article reviews
beamsplitter matrix - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
single-edge dichroic beamsplitter  (IDEX)
90
IDEX single-edge dichroic beamsplitter
Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA <t>IgG1</t> and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.
Single Edge Dichroic Beamsplitter, supplied by IDEX, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/beamsplitters/pm31425794-93-11-14?v=IDEX
Average 90 stars, based on 1 article reviews
single-edge dichroic beamsplitter - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
dispersion compensated 90:10 (r:t) beamsplitter (newport, inc.)  (MKS Instruments)
90
MKS Instruments dispersion compensated 90:10 (r:t) beamsplitter (newport, inc.)
Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA <t>IgG1</t> and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.
Dispersion Compensated 90:10 (R:T) Beamsplitter (Newport, Inc.), supplied by MKS Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/beamsplitters/pm28813154-30-30-31?v=MKS+Instruments
Average 90 stars, based on 1 article reviews
dispersion compensated 90:10 (r:t) beamsplitter (newport, inc.) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
dichroic beamsplitter t505lpxr systems  (VISITRON Inc)
90
VISITRON Inc dichroic beamsplitter t505lpxr systems
Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA <t>IgG1</t> and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.
Dichroic Beamsplitter T505lpxr Systems, supplied by VISITRON Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/beamsplitters/pmc11379887-213-20-23?v=VISITRON+Inc
Average 90 stars, based on 1 article reviews
dichroic beamsplitter t505lpxr systems - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA IgG1 and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.

Journal: Advanced Materials (Deerfield Beach, Fla.)

Article Title: Safe and Localized Lentiviral Gene Delivery via Injectable Mesoporous Scaffolds for Potent Antitumor Immunity

doi: 10.1002/adma.202516661

Figure Lengend Snippet: Alteration of the TME following LVP‐based scaffold vaccination combined with PD‐1 blockade. (a) Experimental design: Mice bearing B16‐OVA tumors were treated with the LVP‐based scaffold vaccine (Vax) on days 5 and 12 post‐tumor inoculation in combination with anti‐PD1 antibody administration ( n = 4 for the untreated group, n = 5 for the Vax+a‐PD1 group). (b) Tumor volumes were measured over time to assess the treatment efficacy. (c) Frequencies of Foxp3 + Tregs within the TME. (d, e) Quantification of tumor‐infiltrating CD4 + (d) and CD8 + (e) T cells per milligram of tumor tissue. (f) M1/M2 macrophage polarization was assessed by the ratio of CD86 to CD206 expression within the F4/80 + macrophage population. (g, h) Concentrations of anti‐OVA IgG1 and IgG2a antibodies in the serum of the mice at the study endpoint. The data in panels (b–h) are presented as the means ± SDs. Statistical analysis was performed using an unpaired Student's t test. p < 0.05 was considered statistically significant.

Article Snippet: The levels of anti‐OVA IgG1 and anti‐OVA IgG2a antibodies were quantified using mouse anti‐OVA IgG1 and mouse anti‐OVA IgG2a antibody assay kits (Chondrex, Inc., Woodinville, WA, USA; Cat# 3013 and 3015) according to the manufacturer's instructions.

Techniques: Expressing